Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

CYP2W1 polymorphism: functional aspects and relation to risk for colorectal cancer.

Stenstedt K, Travica S, Guo J, Barragan I, Pors K, Patterson L, Edler D, Mkrtchian S, Johansson I, Ingelman-Sundberg M.

Pharmacogenomics. 2013 Oct;14(13):1615-22. doi: 10.2217/pgs.13.136.

PMID:
24088132
2.

Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.

Sheldrake HM, Travica S, Johansson I, Loadman PM, Sutherland M, Elsalem L, Illingworth N, Cresswell AJ, Reuillon T, Shnyder SD, Mkrtchian S, Searcey M, Ingelman-Sundberg M, Patterson LH, Pors K.

J Med Chem. 2013 Aug 8;56(15):6273-7. doi: 10.1021/jm4000209. Epub 2013 Jul 26.

PMID:
23844629
3.

Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins.

Travica S, Pors K, Loadman PM, Shnyder SD, Johansson I, Alandas MN, Sheldrake HM, Mkrtchian S, Patterson LH, Ingelman-Sundberg M.

Clin Cancer Res. 2013 Jun 1;19(11):2952-61. doi: 10.1158/1078-0432.CCR-13-0238. Epub 2013 Apr 15.

4.

Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity.

Gomez A, Nekvindova J, Travica S, Lee MY, Johansson I, Edler D, Mkrtchian S, Ingelman-Sundberg M.

Mol Pharmacol. 2010 Dec;78(6):1004-11. doi: 10.1124/mol.110.067652. Epub 2010 Aug 30.

PMID:
20805301
5.

[Hormone replacement therapy with 17 beta-estradiol dydrogesterone: results of a 3-month open-label study].

Grisar J, Travica S, Metka M, Pietschmann P.

Wien Klin Wochenschr. 1999 Dec 23;111(24):1035-43. German.

PMID:
10677891
6.

Clinical profile of a new hormone replacement therapy containing 2 mg 17 beta-estradiol and 10 mg dydrogesterone.

Sator MO, Nagele F, Sator P, Travica S, Gruber D, Huber JC.

Maturitas. 2000 Mar 31;34(3):267-73.

PMID:
10717493

Supplemental Content

Loading ...
Support Center